Results 1 to 10 of about 22,740 (263)
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE [PDF]
Lupus Science and Medicine, 2023 Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific mucocutaneous manifestations in patients with systemic lupus ...
Jun Kang, Aaron Bao
doaj +2 more sources
Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects [PDF]
Anais Brasileiros de Dermatologia, 2023 Cutaneous lupus erythematosus is an autoimmune disease of varied clinical expression, which may present as an exclusively cutaneous disease or be one of the multiple manifestations of systemic lupus erythematosus.
Everton Carlos Siviero do Vale +1 more
doaj +2 more sources
Subacute cutaneous lupus erythematosus with a psoriasiform presentation: A diagnostic clinical conundrum [PDF]
Clinical Case Reports, 2023 Key Clinical Message For practitioners experiencing worsening psoriasis, subacute cutaneous lupus erythematosus (SCLE) with a psoriasiform presentation should be ruled out.
Shazli Razi +4 more
doaj +2 more sources
Cutaneous lupus erythematosus: An update [PDF]
Indian Dermatology Online Journal, 2014 Lupus erythematosus (LE) is a chronic, autoimmune, multisystem disease that displays many diverse symptoms in which localized cutaneous LE (CLE) is on one end of the spectrum and severe systemic LE (SLE) on the other end.
Carina M Grönhagen, Filippa Nyberg
doaj +3 more sources
Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report [PDF]
Frontiers in Immunology, 2023 IntroductionThe anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown promising results in the treatment of unresectable or metastatic squamous cell carcinoma, however, frequently leads to immune-related adverse events limiting ...
Simon Fietz +8 more
doaj +2 more sources
Dermatologic Therapy, 2012 Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease.
Christopher B. Hansen, Kevin W. Dahle
openaire +4 more sources
A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment
Indian Journal of Ophthalmology, 2013 Cutaneous lupus erythematosus is a previously undiagnosed side-effect of ranibizumab. Here, we present a case of an 82-year-old female Caucasian patient with wet age-related macular degeneration.
Marko Andric +4 more
doaj +2 more sources
Skin involvement in systemic lupus erythematosus: a review article [PDF]
Romanian Journal of Rheumatology, 2023 Cutaneous disease is one of the most frequent manifestations of systemic lupus erythematosus (SLE), being classified as LE-specific and LE-nonspecific.
Teodora Baciu +7 more
doaj +1 more source
Cutaneous Lupus Erythematosus [PDF]
JAMA Dermatology, 2014 Lupus erythematosus is an autoimmune disease that presents with either cutaneous or systemic findings. Cutaneous lupus is divided into lupus-specific and -nonspecific skin disease with the former including the acute cutaneous lupus, subacute cutaneous lupus, and chronic cutaneous lupus subtypes. Patients with cutaneous lupus must be evaluated regularly
Ruth Ann Vleugels, A. Brooke Eastham
openaire +5 more sources
Lupus Science and Medicine, 2023 Objective Lupus erythematosus (LE) is a complicated disease with highly heterogeneous clinical manifestations. Previous studies have rarely included all subgroups of patients with lupus and have overlooked the importance of the cutaneous manifestations ...
Qing Zhang +19 more
doaj +1 more source